Sungkyunkwan University · 医学
Professor Yoo-Young Lee's research lab specializes in translational gynecologic oncology, focusing on improving outcomes for patients with cervical, ovarian, and uterine cancers. The lab investigates biomarkers for risk stratification—such as pretreatment neutrophil-to-lymphocyte ratio (NLR)—to guide personalized treatment strategies. It also explores novel therapeutic combinations, including Wee1 inhibitors with radiotherapy, to enhance tumor control while minimizing toxicity. Additionally, the lab contributes to the critical evaluation of clinical advances in gynecologic oncology, particularly in immunotherapy, targeted therapy, and treatment optimization in early and advanced disease.
Figures are computed from collected data and may differ slightly.
Pretreatment NLR may be a cost-effective biomarker to stratify risk of recurrence and death in patients with cervical cancer.
In 2020 series, we summarized the major clinical research advances in gynecologic oncology with providing representative figures of the most influential study for 1 of each 3 gynecologic cancers: cervix, ovary, and uterine corpus. Review for cervical cancer covered targeted agents and immune checkpoint inhibitors, adjuvant radiation therapy or concurrent/sequential chemoradiation therapy after radical hysterectomy in early cervical cancer, radical surgery in early cervical cancer; and prevention
Dynamin 2 is known as a protein involved in cell migration and endocytosis. We aimed to investigate the association between dynamin 2 expressions and tumor progression in early cervical carcinoma (IB1-IIA). Dynamin 2 expression was evaluated at protein level in thirty seven paraffin-embedded, formalin-fixed tissues including four normal cervix tissues and compared with pathologic risk factors for recurrence after surgery in thirty three patients with squamous cell carcinoma of the cervix. The ex
Targeting dynamin 2 may be a promising new approach for the treatment of cervical cancer.
We found that platinum-based combination chemotherapy during adjuvant CCRT after surgery promoted better survival than a weekly cisplatin regimen in ECC patients with pelvic LN metastasis.
In this study, the addition of adjuvant treatment was associated with an OS benefit for patients with LVSI, especially those with grade 3 endometrioid tumors.
Open papers in the app to read, cite, and organize with AI.
